1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
High Tech Pharm. Co., Ltd.

High Tech Pharm. Co., Ltd.

KKRX:106190
9,120.00
KRW
-100.00
(-1.08%)
844.67EPS
25.57P/E
230.73BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6,130.46
5,349.57
4,522.45
5,157.72
6,207.45
6,244.1
5,931.3
7,008.28
6,897.72
9,676.06
10,830.09
7,287.7
6,599.28
6,494.22
Basic EPS, GAAP
983.33
736.67
615.33
496.67
197.33
245.33
-396.67
-296.67
-115.33
552
1,139.33
1,289
1,079
848.71
Free Cash Flow per Basic Share
497.59
74.12
-640.48
-2,060.27
-546.63
-337
30.72
-812.06
571.13
-409.7
-307.89
1,180.71
1,420
190.95
Dividend per Share
133.34
166.62
166.65
100.01
99.93
66.67
33.33
33.36
33.36
33.31
70
66.65
99.98
- -
Book Value per Share
8,071.72
8,658.22
9,141.66
9,515.27
9,610.82
9,719.25
9,271.36
8,947.82
8,829.44
9,398.78
15,093.47
11,261.43
12,289.7
12,114.59
Tangible Book Value per Share
8,071.72
8,658.22
9,141.66
9,515.27
9,610.82
9,719.25
9,271.36
8,947.82
8,829.44
9,398.78
15,093.47
11,261.43
12,289.7
12,114.59
Basic Weighted Avg Shares
11
11
11
11
11
11
11
11
11
11
7
11
11
11
Sales/Revenue/Turnover
65,183
56,897
48,092
54,836
66,050
66,388
63,068
74,462
73,287
102,947
76,772
77,513
70,183
69,050
Operating Margin (%)
18.84
13.86
11.22
9.44
4.95
3.14
-7.17
-4.46
-0.56
4.79
13.14
20.07
18.32
13.32
Depreciation Expense
1,084
920
810
685
601
498
5,503
5,452
5,551
5,545
4,986
5,169
5,417
5,481
Net Income, GAAP
10,455
7,835
6,544
5,280
2,100
2,608
-4,218
-3,152
-1,225
5,873
8,076
13,710
11,475
9,024
Effective Tax Rate (%)
20.44
21.09
20.79
21
17.68
19.77
- -
- -
- -
- -
18.12
19.76
17.01
17.01
Profit Margin (%)
16.04
13.77
13.61
9.63
3.18
3.93
-6.69
-4.23
-1.67
5.7
10.52
17.69
16.35
13.07
Working Capital
57,806
57,750
44,239
25,601
14,886
8,652
13,470
13,544
17,786
20,302
33,786
45,288
58,472
57,994
LT Debt
- -
624
648
674
- -
2,236
5,811
5,481
5,975
64
5,026
34
12
9
Total Equity
85,828
92,064
97,205
101,178
102,194
103,347
98,584
95,144
93,885
99,939
106,994
119,738
130,671
128,810
Return on Invested Capital (%)
11.81
6.79
4.39
4.06
2.62
1.56
- -
- -
- -
- -
6.88
9.8
8.1
5.9
Return on Capital (%)
12.84
8.66
6.81
5.31
2.08
2.47
- -
- -
- -
- -
7.35
11.42
9
7.06
Return on Common Equity (%)
12.84
8.81
6.91
5.32
2.06
2.54
-4.18
-3.25
-1.3
6.06
7.81
12.09
9.17
7.23

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
25
22
18
LT Borrowings
- -
- -
- -
LT Finance Leases
15
12
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
141,839
127,804
230,727

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
66,111
70,991
74,020
Cash, Cash Equivalents & STI
12,855
14,430
8,474
Accounts Receivable, Net
16,105
11,319
15,866
Inventories
34,931
43,727
48,050
Total Current Liabilities
11,901
12,519
16,026
Payables & Accruals
- -
- -
- -
ST Debt
25
22
18
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.14%
6.65%
9.13%
Free Cash Flow
-378.77%
-209.45%
20.25%
Net Income, GAAP
-89.17%
-109.88%
-16.3%
Sales/Revenue/Turnover
5.3%
0.99%
-9.46%
Total Cash Common Dividend
- -
- -
49.99%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19,194
21,945
16,918
19,455
77,513
2025
15,259
23,021
17,865
14,038
70,183
2026
14,126
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
307
414
223
344.53
1,289
2025
205
220.25
356.53
297.03
1,079
2026
-25.11
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
66.65
2025
- -
- -
- -
- -
99.98
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jeong-Soo Kim
Full Time Employees
130
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Eumseong-gun South Korea
IPO Date
Jul 28, 2010
Website
htpharm.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
High Tech Pharm. Co., Ltd. is a South Korea-based pharmaceutical manufacturing company primarily engaged in the research, development, and commercial production of specialized active pharmaceutical ingredients (APIs), with core expertise in sterile bulk antibiotics. Founded in 1998 and headquartered in Chungju, Chungcheongbuk-do, South Korea, the company operates in strategic affiliation with Italy-based pharmaceutical group ACS Dobfar S.p.A. High Tech Pharm. Co., Ltd. develops and manufactures high-purity sterile and non-sterile bulk APIs across multiple therapeutic categories, with primary specialization in carbapenem-class broad-spectrum antibiotics. The company's core product and service offerings comprise sterile injectable APIs, including Imipenem, Cilastatin Sodium, Imipenem and Cilastatin Sodium mixtures, Meropenem, Ertapenem, and Doripenem; advanced antibiotic chemical intermediates; custom synthesis and process optimization services; and comprehensive contract development and manufacturing organization (CDMO) solutions for global pharmaceutical developers. The company serves pharmaceutical manufacturers and healthcare distributors across South Korea, Europe, North America, Latin America, the Middle East, and the Asia-Pacific region, operating production facilities compliant with Good Manufacturing Practice (GMP) guidelines established by the Korean Ministry of Food and Drug Safety, the European Medicines Agency, and the United States Food and Drug Administration. In recent developments, High Tech Pharm. Co., Ltd. has expanded sterile synthesis and aseptic crystallization capacities at its dedicated Chungju production complex to meet rising worldwide demand for injectable carbapenems; deepened supply chain and co-marketing partnerships across regulated global markets via ACS Dobfar's distribution network; advanced regulatory inspection readiness and product dossier submissions for high-potency antibiotic generics; and broadened its CDMO business pipeline to include customized process chemistry and next-generation anti-infective formulation support.